EG 427
Pioneers a new approach in gene therapy called pinpoint gene therapy.
| EUR | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 50 % | 42 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (49200 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
EG427.com is a pioneering biotech startup that is revolutionizing the treatment of chronic diseases through precision molecular therapies. The company's primary focus is on patients suffering from severe localized chronic diseases, particularly those affecting the peripheral nervous system.
EG427.com leverages the potential of non-replicative Herpes Simplex Virus 1 (nrHSV-1) vectors to create a robust gene therapy platform. In simpler terms, they use a harmless version of the Herpes Simplex Virus to deliver therapeutic genes to specific cells in the body. This innovative approach allows for the safe and controlled expression of large genes, which can help modify or even cure chronic diseases.
The company's business model is centered around developing and commercializing this gene therapy platform. They are also investing in the necessary manufacturing infrastructure to support their operations. Their revenue generation strategy is likely based on the successful development, approval, and commercialization of their therapies.
EG427.com's most advanced project is a therapy targeting Type C neurons, which could potentially treat a range of bladder disorders that disproportionately affect women and minorities. This indicates the company's commitment to addressing underserved medical needs and health disparities.
In summary, EG427.com is a promising biotech startup that is harnessing the power of gene therapy to provide safe, effective, and affordable treatments for chronic diseases.
Keywords: Biotech Startup, Precision Molecular Therapies, Chronic Diseases, Gene Therapy, Non-replicative Herpes Simplex Virus 1 (nrHSV-1), Peripheral Nervous System Disorders, Manufacturing Infrastructure, Type C Neurons, Bladder Disorders, Health Disparities.